Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Bevacizumab Biosimilar Aybintio Receives Positive European Opinion

June 26th 2020

The Committee for Medicinal Products for Human Use has recommended approval of Aybintio, a bevacizumab (Avastin) biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.

Dr. Ramakrishnan on the Promise of Biosimilars in Hematology

June 22nd 2020

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

FDA Approves Pfizer’s Pegfilgrastim Biosimilar

June 11th 2020

The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Dr. Cuellar on the Pharmacoeconomic Benefits of Biosimilars

April 30th 2020

Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.

Trastuzumab Biosimilar Ontruzant Enters US Oncology Market

April 15th 2020

Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.

The Future Direction of Biosimilars

March 16th 2020

The Availability of Multiple Biosimilars for 1 Biologic

March 16th 2020

Educating Physicians When Prescribing Biosimilars

March 16th 2020

Pharmacovigilance Requirements for Biosimilar Products

March 16th 2020

Biosimilar Interchangeability in Practice

March 16th 2020

Evidence-Based Extrapolation for Biosimilars

March 16th 2020

The Complexity of Choosing Biosimilars in Oncology

March 16th 2020

The Use of Biosimilars in HER2+ Breast Cancer

March 16th 2020

Biosimilar Use in the Treatment of NSCLC

March 16th 2020

Decision Makers for Formulary Approval of Biosimilars

March 16th 2020

The Adoption and Choice of Biosimilars

March 16th 2020

An Overview of Biosimilarity

March 16th 2020

FDA Reviewing Bevacizumab Biosimilar

March 6th 2020

The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab.

O'Regan Shares Insight on Biosimilar Revolution in Oncology

February 19th 2020

Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.

Schwartzberg Sheds Light on Rise of Biosimilars in Oncology

February 6th 2020

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.